candesartan has been researched along with Diabetic Glomerulosclerosis in 48 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether the angiotensin-receptor blocker candesartan compared with placebo affects microalbuminuria incidence or rate of change in albuminuria in type 1 and type 2 diabetes." | 9.14 | Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. ( Bilous, R; Chaturvedi, N; Fuller, J; Klein, R; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2009) |
| "This is the second part in a series of papers dealing with various aspects of clinical pharmacology of the first AT1-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 8.82 | [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| "Candesartan is a novel high-affinity type 1 AT(1)-receptor blocker characterized by prolonged binding to and slow dissociation from the receptor." | 6.42 | [Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension]. ( Ivanova, NA; Preobrazhenskiĭ, DV; Sidorenko, BA; Soplevenko, AV; Stetsenko, TM, 2004) |
| "To determine whether the angiotensin-receptor blocker candesartan compared with placebo affects microalbuminuria incidence or rate of change in albuminuria in type 1 and type 2 diabetes." | 5.14 | Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. ( Bilous, R; Chaturvedi, N; Fuller, J; Klein, R; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2009) |
| "We evaluated the optimal dose of the angiotensin II receptor antagonist candesartan cilexetil for renoprotection as reflected by short-term changes in albuminuria in hypertensive type 2 diabetic patients with nephropathy." | 5.10 | Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study. ( Carstensen, B; Christensen, PK; Hansen, BV; Parving, HH; Rossing, K, 2003) |
| "We previously reported that the angiotensin II type 1 receptor antagonist candesartan was effective in reducing blood pressure and microalbuminuria in hypertensive patients with diabetic nephropathy after angiotensin-converting enzyme (ACE) inhibitors were replaced due to side effects." | 5.10 | Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy. ( Hayashi, K; Saruta, T; Sato, A; Tabata, M, 2003) |
| "The main objective of the CALM (Candesartan And Lisinopril Microalbuminuria) study is to assess the effect of a dual blockade of the renin-angiotensin system--using both an angiotensin converting enzyme inhibitor (ACE-I) and an angiotensin II type 1 receptor blocker--in patients with type 2 diabetes, high blood pressure and microalbuminuria." | 5.09 | [Clinical study of the month. The CALM study assessing the combination of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist in the treatment of diabetic nephropathy]. ( Philips, JC; Scheen, AJ; Weekers, L, 2001) |
| "This is the second part in a series of papers dealing with various aspects of clinical pharmacology of the first AT1-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 4.82 | [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| "The introduction of Angiotensin II receptor blockers (ARB) in 1995 was another milestone in the pharmacological management of hypertension." | 4.82 | [Angiotensin II receptor blockers--evidence along the cardiovascular continuum]. ( Battegay, E; Zeller, A, 2005) |
| "We performed a post hoc analysis in the Diabetic Retinopathy Candesartan Trials (DIRECT-Protect 2 study), a multi centric randomized clinical controlled trial." | 3.85 | Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. ( Bilous, R; Chaturvedi, N; de Zeeuw, D; Fuller, J; Klein, R; Lambers Heerspink, H; Lindhardt, M; Mischak, H; Orchard, T; Parving, HH; Persson, F; Porta, M; Rossing, P; Stalmach, A; Zürbig, P, 2017) |
| " After 16 weeks, they were randomized into 4 groups (n = 10 each) with comparable proteinuria: (1) control group sacrificed immediately for baseline data, and groups gavaged daily for 8 weeks with (2) placebo, (3) perindopril (1 mg/kg/day), or (4) candesartan (10 mg/kg/day)." | 3.75 | Functional and partial morphological regression of established renal injury in the obese zucker rat by blockade of the renin-angiotensin system. ( Amann, K; Boor, P; Heidland, A; Lill, M; Sebeková, K, 2009) |
| "Time-dependent elevation of MCP-1 expression was dramatically suppressed by treatment with the angiotensin-converting enzyme inhibitor enalapril or the AT1 receptor antagonist candesartan, and was closely associated with effects on proteinuria and glomerular macrophage number." | 3.70 | Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. ( Brenner, BM; Kato, S; Lee, KW; Luyckx, VA; MacKenzie, HS; Ots, M; Troy, JL; Ziai, F, 1999) |
| "Sixty-eight diabetic nephropathy patients with microalbuminuria were randomly allocated to 1 of 4 treatment groups: losartan 100 mg/day (group A), candesartan 12 mg/day (group B), olmesartan 40 mg/day (group C), or telmisartan 80 mg/day (group D)." | 2.75 | Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy. ( Fujiwara, N; Koide, H; Nakamura, T; Sato, E; Sugaya, T; Ueda, Y, 2010) |
| " The authors randomly assigned 269 patients who had persistent proteinuria (> or =1 g/d) despite 7 wk of treatment with the highest approved dosage of candesartan (16 mg/d) to 16, 64, or 128 mg/d candesartan for 30 wk." | 2.74 | Supramaximal dose of candesartan in proteinuric renal disease. ( Burgess, E; Chiu, A; Muirhead, N; Pichette, V; Rene de Cotret, P; Tobe, S, 2009) |
| "Aldosterone is an important pathogenetic factor, independent of the renin-angiotensin system in cardiovascular and renal disease." | 2.73 | Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. ( Karashima, S; Oda, N; Takata, H; Takeda, Y; Usukura, M; Yamagishi, M; Yamamoto, Y; Yoneda, T, 2007) |
| "There was a wide range of changes in RPF and GFR in response to the two agents, each administered at the top of its dose-response range." | 2.71 | Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. ( Fisher, ND; Gordon, MS; Hollenberg, NK; Laffel, LM; Lansang, MC; Perkins, B; Price, DA; Williams, GH, 2003) |
| "In patients with type 2 diabetes and nephropathy, dual blockade of the renin system with an angiotensin-converting enzyme inhibitor and angiotensin receptor blocker significantly reduces albuminuria and, thus, may be renoprotective even when the doses of the agents are reduced by one half." | 2.71 | Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy. ( Fujisawa, T; Ikegami, H; Kawabata, Y; Nishino, M; Noso, S; Ogihara, T; Ono, M, 2005) |
| "Twenty-eight patients who had type 1 diabetes and known diabetic renal disease and had a persistently elevated albumin creatinine ratio (ACR) > 10 mg/mmol despite office BP recordings < or = 140/80 mmHg on maximal recommended dose of the ACEI lisinopril were studied." | 2.71 | Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease. ( Bilous, R; Karalliedde, J; Krimholtz, MJ; Thomas, S; Viberti, G, 2005) |
| "Candesartan treatment in macroalbuminuric patients significantly changed 15 of the 113 polypeptides in the diabetic renal damage pattern toward levels in normoalbuminuric patients." | 2.71 | Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. ( Christensen, PK; Hillmann, M; Kaiser, T; Mischak, H; Parving, HH; Rossing, K; Walden, M, 2005) |
| "Candesartan is a novel high-affinity type 1 AT(1)-receptor blocker characterized by prolonged binding to and slow dissociation from the receptor." | 2.42 | [Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension]. ( Ivanova, NA; Preobrazhenskiĭ, DV; Sidorenko, BA; Soplevenko, AV; Stetsenko, TM, 2004) |
| "Arterial hypertension is a major risk factor for microangiopathic diabetic complications and associated with an increased cardiovascular morbidity and mortality." | 2.41 | [Angiotensin II type-1 receptor antagonists and diabetes mellitus]. ( Schernthaner, G; Schnack, C, 2001) |
| "Diabetic nephropathy is one of the most common causes of end-stage kidney disease." | 1.40 | Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats. ( El-Moselhy, MA; Hofni, A; Khalifa, MM; Taye, A, 2014) |
| "Diabetic nephropathy is a leading cause of end-stage renal disease." | 1.36 | The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. ( Allen, TJ; Calkin, AC; Cooper, ME; Forbes, JM; Giunti, S; Jandeleit-Dahm, KA; Thomas, MC, 2010) |
| "Treatment with candesartan, but not hydralazine, reduced these values to levels in db/m mice." | 1.35 | Urinary oxidative stress markers closely reflect the efficacy of candesartan treatment for diabetic nephropathy. ( Hashimoto, T; Hirawa, N; Imai, N; Ishigami, T; Kihara, M; Kitamura, H; Kiuchi, Y; Nomura, K; Tamura, K; Toya, Y; Umemura, S; Yasuzaki, H; Yoshida, S, 2009) |
| "In candesartan-treated DM rats, UT-A3 increased in IM tip (160 +/- 14%) and base (210 +/- 19%)." | 1.35 | Candesartan augments compensatory changes in medullary transport proteins in the diabetic rat kidney. ( Blount, MA; Kent, KJ; Klein, JD; Price, SR; Sands, JM; Smith, TD, 2008) |
| "Treatment with candesartan attenuated all of these changes and prevented significant albuminuria." | 1.32 | Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. ( Fan, Q; Gohda, T; Gu, L; Horikoshi, S; Kobayashi, M; Liao, J; Suzuki, Y; Tomino, Y; Wang, LN; Yamashita, M, 2004) |
| "Early proteinuric diabetic nephropathy increases renal expression of the p47phox component of NAD(P)H oxidase and eNOS with increased indices of systemic and renal oxidative/nitrosative stress." | 1.31 | Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. ( Fujita, T; Goto, A; Onozato, ML; Tojo, A; Wilcox, CS, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.08) | 18.2507 |
| 2000's | 37 (77.08) | 29.6817 |
| 2010's | 10 (20.83) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hofni, A | 1 |
| El-Moselhy, MA | 1 |
| Taye, A | 1 |
| Khalifa, MM | 1 |
| Lindhardt, M | 1 |
| Persson, F | 1 |
| Zürbig, P | 1 |
| Stalmach, A | 1 |
| Mischak, H | 2 |
| de Zeeuw, D | 1 |
| Lambers Heerspink, H | 1 |
| Klein, R | 2 |
| Orchard, T | 2 |
| Porta, M | 2 |
| Fuller, J | 2 |
| Bilous, R | 3 |
| Chaturvedi, N | 2 |
| Parving, HH | 5 |
| Rossing, P | 1 |
| Callera, GE | 1 |
| Antunes, TT | 1 |
| Correa, JW | 1 |
| Moorman, D | 1 |
| Gutsol, A | 1 |
| He, Y | 1 |
| Cat, AN | 1 |
| Briones, AM | 1 |
| Montezano, AC | 1 |
| Burns, KD | 1 |
| Touyz, RM | 1 |
| Sebeková, K | 1 |
| Lill, M | 1 |
| Boor, P | 1 |
| Heidland, A | 1 |
| Amann, K | 1 |
| Yoshida, S | 1 |
| Hashimoto, T | 1 |
| Kihara, M | 1 |
| Imai, N | 1 |
| Yasuzaki, H | 1 |
| Nomura, K | 1 |
| Kiuchi, Y | 1 |
| Tamura, K | 1 |
| Ishigami, T | 1 |
| Hirawa, N | 1 |
| Toya, Y | 1 |
| Kitamura, H | 1 |
| Umemura, S | 1 |
| Ikeda, H | 1 |
| Hamamoto, Y | 1 |
| Honjo, S | 1 |
| Nabe, K | 1 |
| Wada, Y | 1 |
| Koshiyama, H | 1 |
| Kuwabara, T | 1 |
| Mori, K | 1 |
| Mukoyama, M | 1 |
| Kasahara, M | 1 |
| Yokoi, H | 1 |
| Saito, Y | 1 |
| Yoshioka, T | 1 |
| Ogawa, Y | 1 |
| Imamaki, H | 1 |
| Kusakabe, T | 1 |
| Ebihara, K | 1 |
| Omata, M | 1 |
| Satoh, N | 1 |
| Sugawara, A | 1 |
| Barasch, J | 1 |
| Nakao, K | 1 |
| Burgess, E | 1 |
| Muirhead, N | 1 |
| Rene de Cotret, P | 1 |
| Chiu, A | 1 |
| Pichette, V | 1 |
| Tobe, S | 1 |
| Shimizu, H | 1 |
| Uehara, Y | 1 |
| Ohsaki, A | 1 |
| Okada, S | 1 |
| Mori, M | 1 |
| Sjølie, AK | 1 |
| Fukuda, M | 1 |
| Nakamura, T | 2 |
| Kataoka, K | 1 |
| Nako, H | 1 |
| Tokutomi, Y | 1 |
| Dong, YF | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Naviglio, S | 1 |
| Pirozzi, F | 1 |
| Giunti, S | 1 |
| Calkin, AC | 1 |
| Forbes, JM | 1 |
| Allen, TJ | 1 |
| Thomas, MC | 1 |
| Cooper, ME | 1 |
| Jandeleit-Dahm, KA | 1 |
| Fujiwara, N | 1 |
| Sato, E | 1 |
| Ueda, Y | 1 |
| Sugaya, T | 1 |
| Koide, H | 1 |
| Kuriyama, S | 2 |
| Otsuka, Y | 1 |
| Ueda, H | 1 |
| Sugano, N | 1 |
| Yoshizawa, T | 1 |
| Yamada, T | 1 |
| Hosoya, T | 2 |
| Takata, H | 2 |
| Takeda, Y | 2 |
| Zhu, A | 1 |
| Cheng, Y | 1 |
| Yoneda, T | 2 |
| Demura, M | 1 |
| Yagi, K | 1 |
| Karashima, S | 2 |
| Yamagishi, M | 2 |
| Patinha, D | 1 |
| Fasching, A | 1 |
| Pinho, D | 1 |
| Albino-Teixeira, A | 1 |
| Morato, M | 1 |
| Palm, F | 1 |
| Hollenberg, NK | 1 |
| Price, DA | 1 |
| Fisher, ND | 1 |
| Lansang, MC | 1 |
| Perkins, B | 1 |
| Gordon, MS | 1 |
| Williams, GH | 1 |
| Laffel, LM | 1 |
| Tomonari, H | 1 |
| Tokudome, G | 1 |
| Horiguchi, M | 1 |
| Hayashi, H | 1 |
| Kobayashi, H | 1 |
| Ishikawa, M | 1 |
| Rossing, K | 3 |
| Christensen, PK | 2 |
| Hansen, BV | 1 |
| Carstensen, B | 1 |
| Jacobsen, P | 1 |
| Pietraszek, L | 1 |
| Sidorenko, BA | 2 |
| Preobrazhenskiĭ, DV | 2 |
| Stetsenko, TM | 2 |
| Tarykina, EV | 1 |
| Tsurko, VV | 1 |
| Mimran, A | 1 |
| Alfaro, V | 1 |
| Sato, A | 1 |
| Tabata, M | 1 |
| Hayashi, K | 1 |
| Saruta, T | 1 |
| Song, JH | 2 |
| Lee, SW | 3 |
| Suh, JH | 1 |
| Kim, ES | 1 |
| Hong, SB | 1 |
| Kim, KA | 1 |
| Kim, MJ | 2 |
| Banes, AK | 1 |
| Shaw, S | 1 |
| Jenkins, J | 1 |
| Redd, H | 1 |
| Amiri, F | 1 |
| Pollock, DM | 1 |
| Marrero, MB | 1 |
| Soplevenko, AV | 1 |
| Ivanova, NA | 1 |
| Makino, H | 1 |
| Fan, Q | 1 |
| Liao, J | 1 |
| Kobayashi, M | 1 |
| Yamashita, M | 1 |
| Gu, L | 1 |
| Gohda, T | 1 |
| Suzuki, Y | 1 |
| Wang, LN | 1 |
| Horikoshi, S | 1 |
| Tomino, Y | 1 |
| Fujisawa, T | 1 |
| Ikegami, H | 1 |
| Ono, M | 1 |
| Nishino, M | 1 |
| Noso, S | 1 |
| Kawabata, Y | 1 |
| Ogihara, T | 1 |
| Zeller, A | 1 |
| Battegay, E | 1 |
| Krimholtz, MJ | 1 |
| Karalliedde, J | 1 |
| Thomas, S | 1 |
| Viberti, G | 1 |
| Walden, M | 1 |
| Hillmann, M | 1 |
| Kaiser, T | 1 |
| Cha, SH | 1 |
| Lee, HJ | 1 |
| Park, GH | 1 |
| Ogawa, S | 2 |
| Mori, T | 2 |
| Nako, K | 2 |
| Kato, T | 1 |
| Takeuchi, K | 2 |
| Ito, S | 2 |
| García Donaire, JA | 1 |
| Ruilope, LM | 1 |
| Tsubono, Y | 1 |
| Usukura, M | 1 |
| Oda, N | 1 |
| Yamamoto, Y | 1 |
| Perrin, NE | 1 |
| Jaremko, GA | 1 |
| Berg, UB | 1 |
| Blount, MA | 1 |
| Sands, JM | 1 |
| Kent, KJ | 1 |
| Smith, TD | 1 |
| Price, SR | 1 |
| Klein, JD | 1 |
| Kageyama, S | 1 |
| Kato, S | 1 |
| Luyckx, VA | 1 |
| Ots, M | 1 |
| Lee, KW | 1 |
| Ziai, F | 1 |
| Troy, JL | 1 |
| Brenner, BM | 1 |
| MacKenzie, HS | 1 |
| Mogensen, CE | 1 |
| Ruilope, L | 1 |
| Chen, BH | 1 |
| Philips, JC | 1 |
| Weekers, L | 1 |
| Scheen, AJ | 1 |
| Schnack, C | 1 |
| Schernthaner, G | 1 |
| Onozato, ML | 1 |
| Tojo, A | 1 |
| Goto, A | 1 |
| Fujita, T | 1 |
| Wilcox, CS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Randomised, Dose Ranging, Multi-Centre, Phase IIIb Study to Evaluate the Efficacy and Safety of High Doses of Candesartan Cilexetil (Atacand®) on the Reduction of Proteinuria in the Treatment of Subjects With Hypertension and Moderate to S[NCT00242346] | Phase 3 | 270 participants | Interventional | 2003-04-30 | Completed | ||
| Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients Without Retinopathy.[NCT00252733] | Phase 3 | 5,238 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 2 Diabetic Patients With Retinopathy.[NCT00252694] | Phase 3 | 4,717 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| DIRECT: DIabetic Retinopathy Candesartan Trials. Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients With Retinopathy.[NCT00252720] | Phase 3 | 1,850 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy[NCT00367562] | Phase 4 | 20 participants | Interventional | 1996-01-31 | Completed | ||
| Studies of Early Diabetic Glomerulopathy-the Relation Between Histopathology, Kidney Function and Metabolic Control. Natural History and Effect of ARB[NCT00328302] | Phase 4 | 13 participants | Interventional | 2000-09-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Two steps were defined as either a 1-step change in each eye or as a 2-step change in one eye only. ETDRS is a scale with 11 steps (1-11, where a score of 1 represents no retinopathy and a score of 11 represents proliferative retinopathy). A generalized log-rank test was used to test difference between treatments. (NCT00252733)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 178 |
| Placebo | 217 |
An estimate of the slope from fitting a linear regression of log(UAER) over time for each patient. (NCT00252733)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/year (Least Squares Mean) |
|---|---|
| Candesartan | 0.510 |
| Placebo | 0.543 |
3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments. (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 161 |
| Placebo | 182 |
3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 180 |
| Placebo | 136 |
Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs. (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 192 |
| Placebo | 193 |
An estimate of the slope from fitting a linear regression of log(UAER) over time (post-randomisation, yearly assessments) for each patient. (NCT00252694)
Timeframe: From Baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/1000 year (Least Squares Mean) |
|---|---|
| Candesartan | 656 |
| Placebo | 718 |
Retinopathy progression was defined as the first occurrence of at least a 3-step increase in the ETDRS severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments. (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 127 |
| Placebo | 124 |
Regression of diabetic retinopathy was defined as at least a 3 step improvement or a persistent 2-step improvement (confirmed in 2 consecutive photography sets) in the Early Treatment of Diabetic Retinopathy Study (ETDRS) severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). (NCT00252720)
Timeframe: From baseline to the end of the study, i.e., 5 years
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 140 |
| Placebo | 139 |
Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs. (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 110 |
| Placebo | 107 |
An estimate of the slope from fitting a linear regression of log (UAER) over time (post-randimisation, yearly assessments) for each patient (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/year (Least Squares Mean) |
|---|---|
| Candesartan | 0.569 |
| Placebo | 0.642 |
9 reviews available for candesartan and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
[Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl C | 2003 |
Candesartan: nephroprotective effects and treatment of diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2003 |
[Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Bipheny | 2004 |
[Early diagnosis of and therapy for patients with diabetic nephropathy].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2004 |
[Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Albuminuria; Angiotensin II; Angiotensin II Ty | 2005 |
Angiotensin receptor blockade in diabetic renal disease--focus on candesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Clinica | 2007 |
[Clinical trials of ACE inhibitors and ARB for treatment of patients with hypertension, heart failure, and diabetic nephropathy in Japan--special reference to the dosage schedule and adverse effects].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2008 |
RAS blockade: new possibilities in the treatment of complications of diabetes.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazo | 2000 |
[Angiotensin II type-1 receptor antagonists and diabetes mellitus].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2001 |
19 trials available for candesartan and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Asian People; Benzimidazoles; Benzoates; | 2009 |
Supramaximal dose of candesartan in proteinuric renal disease.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetic N | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabet | 2010 |
Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus.
Topics: Adolescent; Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles | 2003 |
Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihy | 2002 |
Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study.
Topics: Aged; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cros | 2003 |
Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 2003 |
Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2003 |
The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidaz | 2003 |
Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2005 |
Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease.
Topics: Adult; Aged; Albuminuria; Amlodipine; Benzimidazoles; Biphenyl Compounds; Cross-Over Studies; Diabet | 2005 |
Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns.
Topics: Albuminuria; Amino Acid Sequence; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biomarker | 2005 |
Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benz | 2006 |
Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimid | 2006 |
Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2007 |
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Co | 2007 |
The effects of candesartan on diabetes glomerulopathy: a double-blind, placebo-controlled trial.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biopsy; Biphenyl Compounds; Blood Pr | 2008 |
[Clinical study of the month. The CALM study assessing the combination of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist in the treatment of diabetic nephropathy].
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimi | 2001 |
20 other studies available for candesartan and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats.
Topics: Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cyclooxygenase 2; Diabete | 2014 |
Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biomarkers; Biphenyl Com | 2017 |
Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2/AT2R/Mas axis.
Topics: Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Benzimidazoles; B | 2016 |
Functional and partial morphological regression of established renal injury in the obese zucker rat by blockade of the renin-angiotensin system.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimid | 2009 |
Urinary oxidative stress markers closely reflect the efficacy of candesartan treatment for diabetic nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihype | 2009 |
Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Albumins; Angiotensin II Type 1 Receptor Blockers; Animal | 2009 |
Administration time difference of candesartin effect on albuminuria in type 2 diabetic patients.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2010 |
Renin-Angiotensin system blockade for diabetic nephropathy prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Typ | 2010 |
The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Benzimidazoles; Biphenyl Compou | 2010 |
Augmented antihypertensive effect of a fixed combination formula of candesartan and hydrochlorothiazide combined with furosemide in a patient on peritoneal dialysis.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Co | 2011 |
Protective effects of mineralocorticoid receptor blockade against neuropathy in experimental diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blotting, West | 2012 |
Angiotensin II contributes to glomerular hyperfiltration in diabetic rats independently of adenosine type I receptors.
Topics: Adenosine A1 Receptor Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; | 2013 |
Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimida | 2004 |
Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Body Weight; Di | 2004 |
Candesartan augments compensatory changes in medullary transport proteins in the diabetic rat kidney.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aquaporin 2; Benzimidazoles; Biphenyl Compounds; D | 2008 |
Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Base Sequence; | 1999 |
Diabetic nephropathy: evidence for renoprotection and practice.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting E | 2000 |
Combination treatment effective option for hypertensive, diabetic patients with microalbuminuria.
Topics: Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetic Nephropathies; Do | 2001 |
Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2002 |